Exclusive: EU in advanced talks with Johnson & Johnson on COVID-19 vaccine deal – sources

Exclusive: EU in advanced talks with Johnson & Johnson on COVID-19 vaccine deal – sources
BRUSSELS (Reuters) – The European Commission is in advanced talks with pharmaceutical giant Johnson & Johnson to reserve or buy up-front doses of its COVID-19 vaccine under development, two officials familiar with the talks told Reuters. FILE PHOTO: The U.S. flag is seen over the company logo for Johnson & Johnson to celebrate the 75th anniversary of the company’s listing... Read More

Bayer scraps U.S. plans to produce crop chemical blocked by court

Bayer scraps U.S. plans to produce crop chemical blocked by court
FILE PHOTO: The logo of Bayer AG is pictured at the facade of the historic headquarters of the German pharmaceutical and chemical maker in Leverkusen, Germany, April 27, 2020. REUTERS/Wolfgang Rattay/File Photo CHICAGO (Reuters) – Bayer AG said on Tuesday it will scrap a nearly $1 billion project to produce the chemical dicamba in the United States, but said the... Read More

Japan’s Takeda to sell some Asia-focused drugs to Celltrion for $278 million

Japan’s Takeda to sell some Asia-focused drugs to Celltrion for $278 million
FILE PHOTO: Takeda Pharmaceutical Co. President and Chief Executive Officer Christophe Weber attends a news conference in Tokyo, Japan May 9, 2018. REUTERS/Kim Kyung-Hoon/File Photo (Reuters) – Takeda Pharmaceutical Co Ltd (4502.T) has agreed to sell a portfolio of over-the-counter and prescription drugs marketed in the Asia Pacific region to South Korea’s Celltrion Inc (068270.KS) for $278 million, it said... Read More

U.S. states accuse 26 drugmakers of generic drug price fixing in sweeping lawsuit

U.S. states accuse 26 drugmakers of generic drug price fixing in sweeping lawsuit
(Reuters) – Twenty-six drug manufacturers were sued on Wednesday by the attorneys general of most U.S. states and several territories, which accused them of conspiring to reduce competition and drive up generic drug prices. FILE PHOTO: A logo for Pfizer is displayed on a monitor on the floor at the New York Stock Exchange (NYSE) in New York, U.S., July... Read More

Japan’s Fujifilm to spend $928 million to double capacity of Danish drug facility

Japan’s Fujifilm to spend $928 million to double capacity of Danish drug facility
FILE PHOTO: Fujifilm’s company logo (top) is seen at its exhibition hall nearby the headquarters of Fujifilm Holdings Corp in Tokyo, Japan June 12, 2017. REUTERS/Kim Kyung-Hoon/File Photo TOKYO (Reuters) – Fujifilm Holdings Corp (4901.T) will spend $928 million to double capacity at a drug manufacturing facility in Denmark, which it has pledged to use in producing COVID-19 treatments, as... Read More

Corning wins U.S. funding to boost glass vial manufacturing for COVID-19 therapies

Corning wins U.S. funding to boost glass vial manufacturing for COVID-19 therapies
FILE PHOTO: A screen displays the logo for Corning Inc. at the New York Stock Exchange (NYSE) in New York, U.S., November 18, 2019. REUTERS/Brendan McDermid (Reuters) – Corning Inc (GLW.N) said on Tuesday it would receive $204 million from the U.S. government to boost the manufacturing capacity of its glass vials after the company was selected as a packaging... Read More

Elanco wins conditional EU antitrust okay for $7.6 billion Bayer deal

Elanco wins conditional EU antitrust okay for $7.6 billion Bayer deal
FILE PHOTO: The logo of Bayer AG is pictured at the facade of the historic headquarters of the German pharmaceutical and chemical maker in Leverkusen, Germany, April 27, 2020. REUTERS/Wolfgang Rattay BRUSSELS (Reuters) – Elanco Animal Health (ELAN.N) secured EU antitrust clearance on Monday to buy Bayer’s (BAYGn.DE) veterinary drugs unit after pledging to sell some products to address competition... Read More

Gilead shares rise on report of AstraZeneca’s interest in megamerger

Gilead shares rise on report of AstraZeneca’s interest in megamerger
(Reuters) – Shares of Gilead Sciences Inc (GILD.O) rose as much as 3% on Monday after a report said the U.S. drugmaker had been approached by Britain’s AstraZeneca (AZN.L) for a possible merger to form one of the world’s largest drug companies. AstraZeneca contacted Gilead last month but the U.S. company, which is testing its drug remdesivir as a COVID-19... Read More

Gilead shares rise 5% on report of AstraZeneca’s interest in megamerger

Gilead shares rise 5% on report of AstraZeneca’s interest in megamerger
(Reuters) – Shares of U.S. drugmaker Gilead Sciences Inc (GILD.O) rose over 5% in premarket trading on Monday after a report it had been approached by Britain’s AstraZeneca (AZN.L) for a possible merger to form one of the world’s largest drug companies. AstraZeneca’s shares fell 2.4% on the FTSE 100 as investors contemplated a large payout and questioned the rationale... Read More